Login / Signup

Dupilumab Improves Long-term Outcomes in Patients With Uncontrolled, Moderate-to-Severe GINA-Based Type 2 Asthma, Irrespective of Allergic Status.

Klaus Friedrich RabeIan Douglas PavordWilliam Walter BusseGeoffrey L ChuppKenji IzuharaArman AltincatalRebecca GallNami Pandit-AbidYamo DenizPaul J RoweJuby A Jacob-NaraAmr Radwan
Published in: Allergy (2023)
Long-term treatment with dupilumab reduced exacerbation rates, and improved lung function and asthma control in patients with asthma with type 2 inflammation as per current GINA guidance and irrespective of evidence of allergic asthma.
Keyphrases
  • lung function
  • chronic obstructive pulmonary disease
  • allergic rhinitis
  • cystic fibrosis
  • air pollution
  • atopic dermatitis
  • oxidative stress
  • early onset
  • high intensity
  • drug induced
  • acute respiratory distress syndrome